Animal skin-derived collagen peptides with a characteristic Gly-Pro-Y sequence potently inhibit α-glucosidase and DPP-IV enzymes, demonstrating multiple blood sugar-lowering mechanisms relevant to type 2 diabetes management.
Dual enzyme inhibitionAnimal skin-derived peptides with Gly-Pro-Y sequences competitively inhibit both α-glucosidase (sugar absorption) and DPP-IV (GLP-1 degradation), providing two complementary blood sugar-lowering mechanisms
What the researchers found
Animal skin collagen contains a unique Gly-Pro-Y sequence structure that is key to producing highly active blood sugar-lowering peptides. These peptides (ASHP) work through competitive inhibition of α-glucosidase (blocking sugar absorption) and DPP-IV (extending the action of natural incretin hormones like GLP-1). Multi-level blood glucose regulation includes improving insulin resistance as a key mechanism.
AI prediction combined with peptide sequence structural analysis has emerged as a crucial strategy for screening the most active peptides from animal skin hydrolysates. Preparation optimization involves high-temperature collagen extraction followed by physical pretreatment and enzyme-specific hydrolysis.
Why it matters
DPP-IV is the enzyme that degrades GLP-1 — the same peptide targeted by blockbuster drugs like semaglutide. Finding natural food-derived peptides that inhibit DPP-IV offers a dietary approach to extending GLP-1 activity. Additionally, upcycling animal skin waste into valuable bioactive peptides addresses both health and sustainability goals simultaneously.
How the study worked
Narrative review synthesizing recent research on animal skin-derived hypoglycemic peptides. Covers preparation methods (extraction, hydrolysis), structure-activity relationship analysis, enzyme inhibition mechanisms (α-glucosidase, DPP-IV), and multi-pathway blood glucose regulation. Discusses AI-based peptide screening approaches.
What this study cannot tell us
This is a review without new experimental data. Most evidence for blood sugar-lowering effects comes from in vitro enzyme inhibition assays and animal studies, with limited human clinical data. The bioavailability of these peptides after oral consumption is not well established — they may be degraded during digestion before reaching therapeutic targets. The Gly-Pro-Y sequence is common in many collagen sources, making it unclear which specific animal skins produce the most active peptides.
How to read the evidence
This is a narrative review synthesizing evidence primarily from in vitro studies and animal models. While the enzyme inhibition data is robust, clinical evidence for blood sugar-lowering effects in humans is limited. The review provides a comprehensive scientific framework but not clinical validation.
When this study was published
Published in 2026, this review reflects the current state of food-derived bioactive peptide research for diabetes management, including emerging AI-based screening approaches.
The bigger picture
This review connects food science with diabetes pharmacology through peptide biochemistry. The finding that collagen-derived peptides can inhibit DPP-IV — the same target as the drug class sitagliptin (Januvia) — suggests that dietary peptides could complement pharmaceutical approaches to diabetes management. This also represents a sustainability win: converting waste animal skins into health-promoting ingredients.
Questions still open
- Can animal skin-derived peptides survive digestion and reach therapeutic DPP-IV inhibition levels in humans?
- How do these natural DPP-IV inhibitory peptides compare in potency to pharmaceutical DPP-IV inhibitors like sitagliptin?
- Could collagen peptide supplements provide meaningful blood sugar management benefits for people with prediabetes?
Common questions
How do collagen peptides lower blood sugar?
Is this the same as taking a collagen supplement?
Read the original research
Beneficial effect of animal skin-derived bioactive peptides on type 2 diabetes mellitus: A review on preparation, structure-activity relationship, and blood glucose regulation mechanism.
Food research international (Ottawa, Ont.), 227, 118248
Citation
Zheng, Xiaoshan; Guo, Yongxiang; Sun, Dingyan; Shi, Wenzheng; Lu, Ying. (2026). Beneficial effect of animal skin-derived bioactive peptides on type 2 diabetes mellitus: A review on preparation, structure-activity relationship, and blood glucose regulation mechanism.. Food research international (Ottawa, Ont.), 227, 118248. https://doi.org/10.1016/j.foodres.2025.118248